INSR and hyperinsulinism: The role of insulin metabolism in CRPC progression deserves further study because of the increasing prevalence of hyperinsulinemia in the population at risk to develop prostate cancer, and because of the availability of therapies (such as dual small molecule inhibitors of IGF-1R and IR) to target insulin and IGF-1 pathways in patients with advanced disease [16].